Marathon Rotary Club

Wednesday, 12:15pm Meeting at the Marathon Yacht Club

Amgen will lead to preclinical and clinical development and commercialization worldwide fully.

Xencor and Amgen announce strategic collaboration in tumor immunotherapy and inflammation Amgen and Xencor, Inc. announced today that the two companies have entered into a study and license contract to build up and commercialize novel therapeutics in the areas of tumor immunotherapy and inflammation. The collaboration includes molecular engineering by Xencor and the preclinical advancement of bispecific molecules for five programs proposed by Amgen, leveraging XmAb bispecific Fc domains to make half-life extended T cell engagers and dual targeting bispecific antibodies boost stimulation . The agreement also includes a preclinical bispecific T cell engager program fond of CD38 and CD3 for multiple myeloma.

Amerigroup second quarter total revenues increase 6.3 percent to $1.53 billion Amerigroup Corporation today announced that net gain for the next quarter of 2011 was $44.3 million, or $0.83 per diluted share, versus net gain of $67.2 million, or $1.31 per diluted talk about, for the second one fourth of 2010 and compared to $70.5 million, or $1.37 per diluted share, for the first quarter of 2011.53 billion, a 6.3 percent increase versus $1.44 billion in the next quarter of 2010 and compared to $1.54 billion in the first quarter of 2011.